A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
Universal Diagnostics
Summary
To evaluate the performance characteristics of Signal-C™ a plasma circulating free-DNA test, to detect colorectal cancer and advanced precancerous lesions (APL) in an average risk screening population for 45 and over.
Eligibility
- Age range
- 45–84 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: 1. Subjects aged 45-84 years at time of consent 2. Intended to undergo a standard-of-care screening colonoscopy 3. Considered by a physician or healthcare provider as being of 'average risk' for CRC 4. Willing to consent to blood draw prior to bowel preparatory procedures or undergoing colonoscopy ideally within 90 days of the date of the investigational blood draw. 5. Willing to consent to follow-up for one year as per protocol 6. Able and willing to sign informed consent Exclusion Criteria: 1. Undergoing colonoscopy for investigation of CRC risk symptoms 2. Has undergo…
Interventions
- DeviceSignal-C™
Signal-C™ is a qualitative next generation sequencing-based in vitro diagnostic assay that uses targeted hybridization-based capture next-generation sequencing together with bioinformatics and machine learning algorithm for detection and combination of methylation and fragmentation associated DNA marker regions. Signal-C™ utilizes circulating cell-free DNA (cfDNA) isolated from plasma of peripheral whole blood collected via venipuncture in Streck Cell-Free DNA Blood Collection Tubes (BCTs).
Location
- Gastroenterology Consultants of SW VirginiaRaonoke, Virginia